ONECUT2 is active in prostate adenocarcinoma as a lineage plasticity driver [5], but also promotes neuroendocrine prostate cancer (NEPC), a highly aggressive variant that emerges as a result of AR-targeted therapy [6] and ONECUT2 is active during hypoxia signaling [4, 7]. Here, ONECUT2 is linked to prostate adenocarcinoma.